SCHEMBL95051

SCHEMBL95051

[CH2]c1ccc(C(=O)NCCc2ccccc2)cc1

nearest known ligand 0.73

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC2 Q92769 2/20 0.73
HDAC8 Q9BY41 2/20 0.73
HDAC6 Q9UBN7 2/20 0.73
RAB9A P51151 11/20 0.71
NPC1 O15118 10/20 0.71
MLYCD O95822 2/20 0.66
SMN1; SMN2 Q16637 4/20 0.64
MEN1 O00255 2/20 0.64
KMT2A Q03164 2/20 0.64
TAAR1 Q96RJ0 1/20 0.64
MAPT P10636 2/20 0.62
HSD17B10 Q99714 1/20 0.60
L3MBTL1 Q9Y468 1/20 0.60
KDM1A O60341 1/20 0.59
NFKB1 P19838 1/20 0.59
NFKB2 Q00653 1/20 0.59
RELA Q04206 1/20 0.59
HDAC3 O15379 1/20 0.59
HDAC4 P56524 1/20 0.59
HDAC1 Q13547 1/20 0.59

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL94428 0.90 NPC1 (0.79) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL751214 0.88 HDAC2 (0.80) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL27600901 0.87 MEN1 (0.65) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL6841899 0.86 HDAC2 (0.78) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL7282271 0.86 HDAC2 (0.78) HDAC2HDAC8HDAC6RAB9ANPC1
Hydrochloric Acid SCHEMBL28193721 0.86 HDAC2 (0.77) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL2919151 0.85 HDAC2 (0.76) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL13073425 0.85 HDAC2 (0.76) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL6571020 0.85 HDAC2 (1.00) HDAC2HDAC8HDAC6RAB9ANPC1
SCHEMBL96062 0.84 NPC1 (0.75) RAB9ANPC1SMN1; SMN2MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8362252-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-01-29 US disclosed
EP-1797082-B1 CARBOSTYRIL COMPOUND OTSUKA PHARMA CO LTD (JP) 2012-08-29 EP disclosed
EP-2426128-A1 Carbostyril compound Otsuka Pharmaceutical Co., Limited (JP) 2012-03-07 EP disclosed
US-20100261705-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. 2010-10-14 US disclosed
US-7777038-B2 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-08-17 US disclosed
US-20090326008-A1 NF-kappa B Inhibitor OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2009-12-31 US disclosed
EP-2043644-A1 NF- B INHIBITOR Otsuka Pharmaceutical Co., Ltd. (JP) 2009-04-08 EP disclosed
WO-2008010601-A1 NF- ϰB INHIBITOR OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2008-01-24 WO disclosed
US-20070179173-A1 Carbostyril compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-02 US disclosed
EP-1797082-A1 CARBOSTYRIL COMPOUND Otsuka Pharmaceutical Company, Limited (JP) 2007-06-20 EP disclosed
WO-2006035954-A1 CARBOSTYRIL COMPOUND OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-04-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090326008-A1 NF-kappa B Inhibitor NFKBIA, NFKB2, IKBKB HDAC2 423/4885HDAC8 1201/4885HDAC6 1080/4885
US-20070179173-A1 Carbostyril compound GTF2F1, F3, GTF2F2 HDAC2 1170/4885HDAC8 3441/4885HDAC6 2093/4885
US-20100261705-A1 CARBOSTYRIL COMPOUND GTF2F1, F3, GTF2F2 HDAC2 1170/4885HDAC8 3441/4885HDAC6 2093/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.